Semaglutide

Why Researchers Choose Semaglutide

Semaglutide (the long-acting GLP-1 receptor agonist, the compound marketed as Ozempic and Wegovy) is the reference incretin compound for metabolic research, valued because its roughly seven-day half-life gives stable plasma exposure. It is studied wherever GLP-1 receptor pharmacology is the question:

• GLP-1 receptor expression in hypothalamic and pancreatic tissue
• cAMP signalling and glucose-dependent insulin secretion in pancreatic beta cell models
• Receptor-level comparison against newer dual and triple agonists
• Hepatic lipid metabolism research
• Central GLP-1 receptor signalling in neuronal cell models

How Semaglutide Works

Semaglutide is a modified GLP-1 analog carrying a C18 fatty-acid chain that binds reversibly to albumin, which is what extends its half-life to roughly a week and protects it from rapid DPP-4 degradation. It binds the GLP-1 receptor, a class B G-protein coupled receptor signalling through cAMP. The receptor is expressed in pancreatic islets, where its activation is linked to glucose-dependent insulin secretion and reduced glucagon secretion, as well as in the gastrointestinal tract and in hypothalamic regions of the central nervous system.

Semaglutide in Comparison

Semaglutide is a single-receptor (GLP-1) agonist. Other incretin research peptides extend this to two or three receptors (GLP-1, GIP and glucagon), and receptor pharmacology across single-, dual- and triple-receptor compounds is a common research focus.

Storage

Lyophilised vials: store at -20°C, protected from light.

For research purposes only. Not for human consumption.